Company intelligence / Profile preview
Rui-Inno Pharma
Zhuhai, Guangdong, Chinapmc.ncbi.nlm.nih.gov ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Rui-Inno Pharma’s lead asset, MDI‑1228 mesylate gel, is a topical JAK inhibitor that has received FDA IND clearance and is currently in a multicenter Phase 2 clinical trial for chronic ulcerative diabetic foot ulcers. This marks the first time a mainland China-based company has received such approval for this indication in the US. The company also has early-stage assets targeting TGF-beta and FGFR3 for additional indications including urogenital diseases and neoplasms.
- Therapeutic areas
- OncologyEndocrinologyNephrologyDermatology
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Rui-Inno Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rui-Inno Pharma.